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infection: Secondary analysis of a randomizs u m m a r y
Background: In polymorbid patients with bronchopulmonary infection, malnutrition is an independent
risk factor for mortality. There is a lack of interventional data investigating whether providing nutritional
support during the hospital stay in patients at risk for malnutrition presenting with lower respiratory
tract infection lowers mortality.
Methods: For this secondary analysis of a randomized clinical trial (EFFORT), we analyzed data of a
subgroup of patients with confirmed lower respiratory tract infection from an initial cohort of 2028
patients. Patients at nutritional risk (Nutritional Risk Screening [NRS] score 3 points) were randomized
to receive protocol-guided individualized nutritional support to reach protein and energy goals (inter-
vention group) or standard hospital food (control group). The primary endpoint of this analysis was all-
cause 30-day mortality.
Results: We included 378 of 2028 EFFORT patients (mean age 74.4 years, 24% with COPD) into this
analysis. Compared to usual care hospital nutrition, individualized nutritional support to reach caloric
and protein goals showed a similar beneficial effect of on the risk of mortality in the subgroup of res-
piratory tract infection patients as compared to the main EFFORT trial (odds ratio 0.47 [95%CI 0.17 to 1.27,
p ¼ 0.136] vs 0.65 [95%CI 0.47 to 0.91, p ¼ 0.011]) with no evidence of a subgroup effect (p for interaction
0.859). Effects were also similar among different subgroups based on etiology and type of respiratory
tract infection and for other secondary endpoints.
Conclusion: This subgroup analysis from a large nutrition support trial suggests that patients at nutri-
tional risk as assessed by NRS 2002 presenting with bronchopulmonary infection to the hospital likely
have a mortality benefit from individualized inhospital nutritional support. The small sample size andMedicine, Kantonsspital Aarau Tellstrasse, CH-5001, Aarau, Switzerland. Fax: þ41 62 838 4100.
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A. Baumgartner, F. Hasenboehler, J. Cantone et al. Clinical Nutrition xxx (xxxx) xxxlimited statistical power calls for larger nutritional studies focusing on this highly vulnerable patient
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Clinical trial registration: Registered under ClinicalTrials.gov Identifier no. NCT02517476.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Respiratory tract infection poses an important risk to patients,
particularly the polymorbid population is at highest risk formortality
and adverse outcome. The risk may further increase, if patients are
malnourished upon hospital admission or if patients become
malnourished during the hospital stay [1]. In the frail polymorbid
patient population, malnutrition often develops slowly due to
different chronic illnesses causing loss of appetite and cachexia due to
disease-related anorexia and inflammation, loss of muscle mass and
sarcopenia [2e5]. Malnutrition can be found in up to 40% of hospi-
talized patients with community-acquired pneumonia and is asso-
ciatedwith a 2.5-fold increase inmortality [6]. Similar data have also
been reported for patients hospitalized for other types of respiratory
infection including COPDexacerbation andCOVID-19 infectionwith a
high prevalence of malnutrition and worse outcomes in the
malnourished population [7,8]. Specifically, observational research
found strong associations of poor nutritional status with prolonged
length of hospital stay and higher disease severity [9].
To reduce the burden of malnutrition-associated adverse out-
comes, several international nutritional societies and expert com-
mittees have published recommendations for the prevention,
diagnosis and treatment of malnutrition in medical patients in
general, and for patients with lower respiratory tract infections due
to COVID-19 in particular [8,10e13]. However, recommendations
regarding nutritional support in patients with lower respiratory
tract infections are largely based on physiological rationales and
observational studies, and extrapolated from interventional
research looking at general medical inpatients [14,15]. However,
interventional trials specifically focusing on patients with lower
respiratory tract infections are currently largely lacking.
Herein, we performed a preplanned secondary analysis of the
Effect of early nutritional support on Frailty, Functional Outcomes and
Recovery of malnourished medical inpatients Trial (EFFORT) looking
specifically at the population of patients with lower respiratory
tract infections [16]. We tested the hypothesis that protocol-guided
individualized nutritional support to reach protein and energy
goals reduces the risk of mortality and other adverse clinical out-
comes in the subgroup of hospitalized inpatients at nutritional risk
with confirmed infection of the lung.2. Materials and methods
2.1. Study design and patient population
This is a secondary analysis of the EFFORT trial, a pragmatic,
investigator-initiated, open-label, non-blinded, multicenter, ran-
domized, controlled trial. The trial protocol and the main results
were previously published elsewhere [16e18]. The ethics com-
mittee of Northwestern Switzerland (EKNZ; 2014_001) approved
the trial and it was registered at ClinicalTrials.gov in August 2015
(https://clinicaltrials.gov/ct2/show/NCT02517476).
A totalofeight secondaryand tertiarycarehospitals inSwitzerland
participated, including the University Clinic in Aarau, the University
Hospital in Bern, the Cantonal hospitals in Lucerne, Solothurn, St.
Gallen, Muensterlingen and Baselland, and the hospital in Lachen.2
2.2. Patient population and randomization
For the trial, we screened medical patients upon hospital
admission for risk for malnutrition based on the Nutritional Risk
Screening 2002 (NRS 2002) [19]. This nutritional risk score includes
different items about the current nutritional status and about
severity of the underlying disease [20]. Principal inclusion criteria
for the trial were nutritional risk based on a NRS 2002  3 points,
an expected length of stay of >4 days and written informed con-
sent. We excluded patients initially treated in intensive care or a
surgical unit, with inability for oral ingestion of food, with ongoing
nutritional support on admission, terminally ill patients, patients
with a past medical history of gastric bypass, anorexia nervosa,
cystic fibrosis and stem cell transplantation, hospitalized for acute
pancreatitis or liver failure, or patients with any contraindications
for nutritional support. We randomized patients based on an
interactive web-system in a 1:1 ratio to either the intervention
group, receiving individual nutritional support to meet their
nutritional requirements or the control group receiving standard
hospital food.
For this secondary analysis, we only included patients with
confirmed lower respiratory tract infections including community-
acquired pneumonia, viral pneumonia, exacerbation of chronic
obstructive pulmonary disease (COPD) and bronchitis. We collected
data on microbiology of patients including blood cultures, PCT tests
and urine antigen tests. We used the GOLD classification for staging
severity of COPD (Global Initiative for Chronic Obstructive Lung
Disease) [21].2.3. Study intervention
Details of the nutritional intervention, which was in line with
current ESPEN guidelines for polymorbid patients [22], have been
published previously [16,17,23]. In brief, patients, randomized to the
intervention group, received individual nutritional support super-
vised by a registered dietician. To predict energy goals, the weight-
adjusted HarriseBenedict equation was used. A daily protein intake
of 1.2e1.5 g/kg body weight was recommended for the general pop-
ulationwith lower targets for those with an acute renal failure (0.8 g
perkgofbodyweight). Throughout thehospital stay, theachievement
of the individual nutritional planwas reassessed every 24e48 h. If at
least 75% of the energy and protein goals could not be reachedwithin
5 days by oral feeding, an escalation of the nutritional support to
enteral or even parenteral feeding was made. When discharged, di-
etary counselling was offered in combination with a prescription for
an oral nutritional supplements as needed. Patients in the control
group received standard hospital food according to their ability and
desire to eat, with no nutritional consultation and no recommenda-
tion for additional nutritional support.2.4. Outcomes
The primary endpoint of this analysis is all-cause mortality up to
day 30 after inclusion in the trial. To verify outcome information,
trained study nurses performed structured telephone interviews
with all patients 30 days after inclusion. If the patient was unable to
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confirmed their survival status.
Secondary endpoints included major adverse events, major
complications, non-elective hospital readmissionwithin the first 30
days as well as mean length of hospital stay. In line with the initial
EFFORT trial [16,17], major adverse events included all-cause mor-
tality, admission to the intensive care unit from the medical ward,
non-elective hospital readmission after discharge, and major
complications including adjudicated nosocomial infection, respi-
ratory failure, a major cardiovascular event (i.e., stroke, intracranial
bleeding, cardiac arrest, myocardial infarction) or pulmonary em-
bolism, acute renal failure, gastro-intestinal events (including
hemorrhage, intestinal perforation, acute pancreatitis) or a decline
in functional status of 10% or more from admission to day 30
measured by the Barthel's index (scores range from 0 to 100, with
higher scores indicating better functional status) [24]. Detailed
definitions for each component of the primary endpoint of themain
trial were summarized in the original report [16,17].
Protocol adherence was defined by reaching of at least 75% of
protein and calorie goals within 5 days of the hospital stay.
2.5. Statistical analyses
We tested the hypothesis that individualized nutritional support
was superior to standard hospital food in the subgroup of patients
with lower respiratory tract infection. We performed all analyses in
the intention-to-treat population, which included all patients with
lower respiratory tract infection who had undergone randomiza-
tion unless they withdrew consent. For the primary outcome, we
compared frequencies using a chi-square test. We also fitted a lo-
gistic regression model adjusted for main prognostic factors (Bar-
thel's index and NRS 2002 at baseline) and study center as
predefined in the study protocol. We reported adjusted odds ratios
(OR) and corresponding 95% confidence intervals (CI's). We used a
similar statistical approach for secondary endpoints, with use of
Student's T test and linear regression models for continuous out-
comes. We also used the KaplaneMeier method to calculate theFig. 1. Patien
3
probability of all-cause mortality within 30 days of randomization.
Because the sample size of this subgroup was small and not pow-
ered for our primary endpoint, we compared effects to the findings
from the main trial by calculation of interaction analyses (test for
effect modification). We also performed subgroup analyses based
on type of infection and severity of COPD.
We performed all statistical analyses with STATA 15.1 (Stata
Corp, College Station, TX, USA). Statistical significance was consid-
ered for a P value < 0.05 (for a 2-sided test).3. Results
3.1. Patient characteristics and protocol adherence
We analyzed data of 378 patients with confirmed lower respi-
ratory tract infection from an initial cohort of 2028 patients (19%).
Figure 1 shows the patient flow in the overall trial. Patients had a
mean age of 74.4 years and high burden of comorbidities including
COPD in 24.1%. Detailed baseline characteristics are presented in
Table 1 andmain outcomes in Table 2. Baseline characteristics were
well balanced between intervention compared to control group
patients. Overall, in 22.8% of patients, the pathogen causing the
infection of the lung was isolated (17.5% bacteria [streptococcus
pneumonia in 26%], in 4.2% a respiratory virus and in 1.1% a fungus).
Protocol adherence was high and energy and protein goals were
met in 79% and 76% in the intervention group respectively. Energy
and protein intake in the intervention group was significantly
higher compared to control group patients (mean difference in
daily energy intake of 286 kcal (95% CI 226 to 541) and in mean
daily protein intake of 13 g (95%CI 6 to 20). The same was true in
regard to weight adjusted individual targets with significantly
higher intakes of calories (adjusted mean difference of 4.1 kcal/kg/
day, [95%CI 3.3 to 4.9] and protein (adjusted mean difference of
0.14 g/kg/day [95%CI 0.11 to 0.17]) in intervention group compared
to control group patients. Table 3 gives detailed results regarding
nutritional outcomes within the trial.t flow.
Table 1
Baseline characteristics of all patients with lower respiratory tract infections.
Parameter Intervention Control p value
(n ¼ 198) (n ¼ 180)
Sociodemographics
Age (years), mean (SD) 73.5 (13.5) 75.3 (12.7) 0.17
Different age categories, n (%)
60 years 32 (16.2%) 20 (11.1%) 0.35
60e75 years 66 (33.3%) 61 (33.9%)
75 years 100 (50.5%) 99 (55.0%)
Male gender, n (%) 109 (55.1%) 108 (60.0%) 0.33
Comorbidities, n (%)
Pre-existing diagnosis of COPD 41 (20.7%) 50 (27.8%) 0.11
GOLD 1 2 (9%) 3 (10%) 0.85
GOLD 2 9 (41%) 12 (39%)
GOLD 3 6 (27%) 6 (19%)
GOLD 4 5 (23%) 10 (32%)
Coronary heart disease 72 (36.4%) 63 (35.0%) 0.78
Congestive heart failure 58 (29.3%) 54 (30.0%) 0.88
Arterial hypertension 106 (53.5%) 93 (51.7%) 0.72
History of stroke 14 (7.1%) 20 (11.1%) 0.17
Peripheral artery disease 27 (13.6%) 26 (14.4%) 0.82
Chronic kidney disease 68 (34.3%) 52 (28.9%) 0.26
Diabetes mellitus 45 (22.7%) 53 (29.4%) 0.14
Malignancy 77 (38.9%) 65 (36.1%) 0.58
Dementia 16 (8.1%) 12 (6.7%) 0.60
Nutritional assessment
BMI (kg/m2), mean (SD) 24.8 (4.8) 24.9 (5.2) 0.88
Nutritional risk score 2002, n (%)
3 points 50 (25.3%) 54 (30.0%) 0.65
4 points 72 (36.4%) 66 (36.7%)
5 points 57 (28.8%) 47 (26.1%)
>5 points 19 (9.6%) 13 (7.2%)
Pathogens responsible for respiratory tract infection, n (%)
Bacterial pathogen 33 (16.7%) 33 (18.3%) 0.8
Streptococcus pneumonia 11 (33%) 11 (33%)
Legionella pneumonia 4 (9%) 3 (8%)
Bacteria of gastrointestinal origin 3 (7%) 3 (8%)
Mycoplasma pneumonia 3 (7%) 1 (2%)
other 12 (26%) 15 (38%)
Viral infection 10 (5.1%) 6 (3.3%) 0.91
Influenza 6 (60%) 2 (33%)
Metapneumovirus 1 (10%) 1 (17%)
Rhinovirus 3 (30%) 2 (33%)
Other type of virus 0 (0%) 1 (17%)
Fungal infection 3 (1.5%) 1 (0.6%) 0.62
Unknown pathogen 152 (76.8%) 140 (77.8%)
Initial blood results
C-reactive protein (CRP, mg/dl), median (IQR) 106 (41, 182) 116.5 (42, 190) 0.65
White blood count (WBC, x 109 cells per liter), median (IQR) 8.945 (6.75, 13.43) 10.24 (7.88, 14.43) 0.032
BMI, body mass index; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IQR, interquartile range; SD, standard
deviation.
p-values are derived from chi-square tests for categorical variables, Student's T-test for normal distributed and ManneWhitney tests for non-normal distributed (i.e. CRP,
WBC) variables.
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Lower respiratory tract infection patients receiving nutritional
support had a 25%-reduction in the risk of 30-daymortality (22/180
[12.2%] vs 18/198 [9.1%]), which was per se not significant in this
subgroup (odds ratio 0.47 [95%CI 0.17 to 1.27]) but similar to the
significant mortality benefits observed in the overall EFFORTcohort
(OR 0.65, 95% CI 0.47 to 0.91). Therewas no evidence for a subgroup
effect (p for interaction ¼ 0.859). This result was also robust among
the predefined subgroup analyses stratified by evidence of bacterial
infection vs no bacterial infection, streptococcus pneumonia infec-
tion vs. other types of infection, underlying COPD vs no COPD and
underlying severe COPD (GOLD stages 3e4) vs less severe or no
COPD (Fig. 2), with again no significant results in the interaction
analysis.
There were also similar improvements as compared to the main
trial regarding secondary outcomes including major adverse4
outcome (48/198 (26.7%) vs 42/180 (21.2%), OR 0.64 (95%CI 0.28 to
1.44); p for interaction ¼ 0.993) and functional outcome expressed
by a decline of the Barthel index >10% at 30 days (26 (14.4%) vs 21
(10.06%), OR 4.49 (95%CI 0.2 to 1.23); p for interaction ¼ 0.629).
Table 2 (for binary outcomes), Table 3 (for linear outcomes) and
Fig. 2 show results for the different endpoints in patients with
lower respiratory tract infections as compared to the overall
EFFORT trial and also present results from interaction analysis
investigating whether patients with lower respiratory tract in-
fections show a different response to nutritional treatment
compared to the overall EFFORT population.
4. Discussion
Within this secondary analysis of a large randomized clinical
trial, we investigated effects of individualized nutritional support
onmortality and other important clinical outcomes in the subgroup
Table 2
Summary of binary outcomes of patients with respiratory tract infection compared to the overall medical trial (EFFORT) population.
Parameters Intervention
group (n ¼ 198)
Control
group (n ¼ 180)
Odds ratio (OR),
Subgroup analysis
(95% CI and p-value)
Odds ratio (OR),
EFFORT cohort
(95% CI and p-value)
p Interaction
Primary endpoint: mortality at 30 days
All-cause mortality, n (%) 18 (9.1%) 22 (12.2%) 0.47 (0.17, 1.27); p ¼ 0.136 0.65 (0.47, 0.91), p ¼ 0.011 0.859
Secondary outcomes
Adverse outcomesa within 30 days n (%) 42 (21.2%) 48 (26.7%) 0.64 (0.28, 1.44); p ¼ 0.278 0.79 (0.64, 0.97), p ¼ 0.023 0.993
Any major complicationsb within 30 days, n (%) 20 (10.1%) 15 (8.3%) 1.32 (0.45, 3.86); p ¼ 0.61 0.95 (0.68, 1.34), p ¼ 0.788 0.332
Non-elective hospital readmission
within 30 days, n (%)
9 (4.5%) 12 (6.7%) 0.37 (0.03, 4.48); p ¼ 0.435 0.99 (0.73, 1.35), p ¼ 0.958 0.293
Functional outcomes
Decline in functional status> 10% at
30 daysc, n (%)
21 (10.6%) 26 (14.4%) 0.49 (0.2, 1.23); p ¼ 0.129 0.62 (0.4, 0.96), p ¼ 0.034 0.908
SD, standard deviation; OR, odds ratio.
a Composite endpoint consisting of all-cause mortality at 30 days, major complications within 30 days, admission to the intensive care unit from the medical ward and non-
elective readmissions after discharge.
b Composite endpoint consisting of adjudicated nosocomial infection, respiratory failure, a major cardiovascular event (i.e., stroke, intracranial bleeding, cardiac arrest,
myocardial infarction) or pulmonary embolism, acute renal failure, gastro-intestinal events (including hemorrhage, intestinal perforation, acute pancreatitis).
c To estimate decline in functional status, we used Barthel index (score ranging from 0 to 100, with higher scores indicating better functional status) and compared scores at
admission with scores at 30 days. Only surviving patients were included in this analysis.
Table 3
Summary of continuous outcomes of patients with respiratory tract infection compared to the overall medical trial (EFFORT) population.
Parameters Intervention
group (n ¼ 198)
Control
group (n ¼ 180)
Adjusted difference,
Subgroup analysis
(95% CI and p-value)
Adjusted difference,
EFFORT cohort
(95% CI and p-value)
p Interaction
Hospital outcomes
length of stay (days), median (IQR) 7.0 (5.0, 13.0) 8.0 (6.0, 12.0) 1.65 (0.38, 3.68); p ¼ 0.111 0.21 (0.76, 0.35), p ¼ 0.46 0.072
Nutritional intake during first 10 days of hospital stay
Caloric intake (kcal/day), mean (SD) 1426 (569) 1140 (478) 383 (226, 541); p < 0.001 290 (240, 340), p < 0.001 0.223
Weight adjusted caloric intake (kcal/kg/day),
mean (SD)
22.5 (8.9) 17.6 (7.4) 4.5 (2.9, 6.2); p < 0.001 4.1 (3.3, 4.9), p < 0.001 0.380
Protein intake (g/day), mean (SD) 56.0 (21.4) 41.6 (16.1) 13 (7, 20); p < 0.001 10 (8, 12), p < 0.001 0.441
Weight adjusted protein intake (g/kg/day),
mean (SD)
0.84 (0.35) 0.68 (0.29) 0.15 (0.08, 0.21); p < 0.001 0.14 (0.11, 0.17), p < 0.001 0.492
Functional outcomes
Barthel score (points) at day 30, mean (SD) 95.0 (9.0) 95.8 (9.1) 1.63 (4.85, 1.6); p ¼ 0.32 3.26 (0.93, 5.6), p ¼ 0.006 0.185
IQR, interquartile range; SD, standard deviation; OR, odds ratio.
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reduction in 30-day mortality and also strong reductions in the risk
of adverse outcome associated with nutritional support in patients
with lower respiratory tract infections at nutritional risk, which
was similar to the general medical inpatient population of the main
trial (EFFORT).
Overall, the evidence that nutritional support reduces mortality,
complications and length of hospital stay in patients with bacterial
or viral infections remains weak due to lack of larger scale trials
specifically focusing on this population of patients. Also, in our
report, we only had a relatively small group of patients with res-
piratory tract infections importantly limiting the power of the
analysis and results in the subgroup regarding mortality, compli-
cations and other outcomes were not significant per se. However,
We also compared our subgroup analysis to the results of the main
trial for evidence of a subgroup effect, i.e., whether there was evi-
dence that patients with respiratory infection would behave
differently from other rmedical patients in regard to the nutritional
support intervention. Importantly, we did not find that patients
with respiratory infections had a different response to nutritional
support compared to the overall medical population. Therefore, we
believe that the positive effects of nutritional support on mortality
and other secondary outcomes may also be true for patients with
respiratory tract infection at nutritional risk e including COVID-19
patients. Clearly, our data needs validation in an independent and
well powered sample to draw firm conclusions. Such a trial should5
then also investigate whether there are differences in response to
nutritional treatment among patients with severe systemic in-
fections vs those with more local infections, among different types
of pathogens and among patients infected with Sars-CoV 2 (Severe
acute respiratory syndrome coronavirus 2) compared to other
pathogens.
Despite the lack of evidence regarding nutritional support in
non-critically ill patients with infections, there have been several
reports in the general medical patient population showing that
nutritional support in at risk patients has positive effects on out-
comes [3,25e27]. Effects were stronger if subjects were malnour-
ished at admission to the hospital compared to patients classified as
at risk for malnutrition [28]. Importantly, while most studies on the
effect of early nutritional support by oral, enteral order parenteral
route on clinical outcome were performed either in the intensive
care setting, surgical collectives or patients presenting with acute
pancreatitis [29], there are several trials for patients on the medical
ward showing a reduced risk of infectious and non-infectious
complications in treated patients [2,30e33]. To our knowledge,
however, there is no study specifically looking at patients with
lower respiratory tract infection [30e32,34e37]. Herein, we believe
our data provide novel and timely information.
Since the publication of the EPaNIC trial, concerns have been
raised about potential harmful effects of early and high caloric
nutritional support among intensive care patients with sepsis
[38,39]. Casaer et al. found worse clinical outcomes with increased
Fig. 2. Odds ratios for primary and secondary outcomes in pre-specified subgroups (Forest plot). Abbreviations: COPD ¼ chronic obstructive pulmonary disease, GOLD ¼ Global
Initiative for Chronic Obstructive Lung Disease.
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intensive care stay in critically-ill patients treated with parenteral
nutrition in addition to partial enteral nutrition [38]. Yet, the sub-
sequent EDEN trial comparing a full enteral feeding strategy with a
strategy of initial trophic enteral feeding for up to 6 days in
critically-ill patients with an acute lung injury did not observe
worse clinical outcomes [40]. Also, results did not differ in the one-
year follow-up of the EDEN cohort [41]. The EPaNIC trial, however,
included a different patient population in regard to older age,
burden of comorbidities and prevalence of malnutrition [42]. Un-
like in critical care, there is no data suggesting potential harmful
effects of overfeeding on normal medical wards e although high
inflammation has been shown to be an effect modifier on the as-
sociation of nutritional support and outcome [43]. Still, our data
showing improved outcomes of an individualized nutritional
approach for this highly vulnerable population of patients with
respiratory infection is reassuring. Importantly, our approach was
based mainly on optimizing oral intake using hospital kitchen food
with the addition of oral nutritional supplements. Additional EN or
PN was used only in a low number of patients if after 5 days
nutritional goals could not be reached. We thus had little risk of
overfeeding of patients [44].
In our trial, we did not use full-replacement feeding in inter-
vention group patients, but rather aimed to reach at least 75% of
protein (and calorie) goals over 5 days (1.2e1.5 g protein/kg/day) by
use of an individualized nutritional support algorithm according to
a previously published feeding protocol with individual definition
of each patient's nutritional goals [23]. As a result the mean protein
intake during the hospital stay in intervention group patients was
(only) 0.84 g protein/kg/day, which was much higher compared to
control group patients not receiving nutritional support (mean of
0.68 g protein/kg/day), but still not in the optimal range as outlined
in the nutritional protocol. As patients typically showed a stepwise
increase in nutritional intake over the course of the hospital stay, a6
majority of intervention group patients eventually reached their
individual protein (and calorie) goals by day 5 by means of oral
nutrition with no need to escalate to enteral or parenteral routes.
Importantly, it is possible that higher intakes of proteins (and cal-
ories) during the initial hospital stay would have further beneficial
effects on patient outcomes, but this would require a separate trial
with higher specific protein and calorie goals. It is possible that for
such a trial the use of enteral and/or parenteral routes may be
necessary in higher proportions of patients to reach higher goals.
Some researchers have suggested that specific formulae,
generally referred to as immuno-nutrition including high amounts
of arginine, glutamine, branched chain amino acids, n-3 fatty acids,
and nucleotides, may provide further benefit for infection patients
also including COVID-19 patients. Yet, such treatments were not
studied in the EFFORT trial, nor to our knowledge, in any other trial
[45e47]. Still, some data suggest that a diet enriched with eicosa-
pentaenoic acid (EPA) and g-linolenic acid (GLA) may favorably
reduce the pulmonary inflammatory response and support vaso-
dilation and oxygenation in septic patients [48]. These benefits
observed in pre-clinical studies, however, did not result in a clinical
benefit according to a recent Cochrane review focusing on
critically-ill patients with acute respiratory distress syndrome
(ARDS) [49]. There is at least one prospective randomized
controlled trial planned looking specifically at the role of immune-
nutrition for the COVID-19 patient population (https://clinicaltrials.
gov/ct2/show/NCT04249050).
5. Conclusion
This subgroup analysis from a large nutrition support trial
suggests that patients presenting to the hospital with broncho-
pulmonary infection and nutritional risk as assessed by NRS 2002
may show a mortality benefit from individualized inhospital
nutritional support. The small sample size and limited statistical
A. Baumgartner, F. Hasenboehler, J. Cantone et al. Clinical Nutrition xxx (xxxx) xxxpower calls for larger nutritional studies focusing on this highly
vulnerable patient population.
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